People
BioSpace takes a look at the annual compensation for the chief executive officers of vaccine developers.
She succeeds Mission Bio’s current chief executive officer Charlie Silver, who will shift into an advisory role with the company he co-founded.
Davidson is one of three new executives to join Cambridge, Mass.-based Tessera.
The biopharmaceutical industry saw two CEO appointments made today, including Howard J. Federoff, M.D., Ph.D., to Brooklyn ImmunoTherapeutics and Eric Koo to Overland ADCT BioPharma.
Gilead CEO Daniel O’Day navigated the company through the turbulent waters of COVID-19 last year, pushing out the very first approved treatment for treatment of the virus. His reward? A $19 million take home.
He’ll make a return to his former role at SV Health Investors as a Venture Partner.
If you’re one of the 17% of Americans that have been fully vaccinated against SARS-CoV-2, you are probably feeling some level of relief. But the CDC warns not to throw your mask away just yet.
It’s something of the holy grail—run whole genome sequencing on a sample of a person’s blood and identify their risk for disease, all quickly and affordably. Oxford, England’s Genomics, founded in 2014 out of Oxford University by Sir Peter Donnelly, may be getting close.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Several new reports, two by the U.S. CDC, describe just how severely COVID-19 has affected mortality figures in the U.S., and around the world, as well as ripple effects that extended to other forms of death.
PRESS RELEASES